Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate to severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography
Journal of the American Academy of Dermatology | Mar 22, 2018
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, -2, and -3
Journal of the American Academy of Dermatology | Mar 20, 2018
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis
Journal of the European Academy of Dermatology and Venereology | Mar 14, 2018
Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials
Journal of the European Academy of Dermatology and Venereology | Mar 12, 2018